IMUNON’s VP of R&D to Present at the Vaccines Summit-2023
Dr. Jean Boyer to highlight updated data showing the advantages of IMUNON’s PlaCCine modality and its applicability to multiple pathogens LAWRENCEVILLE, N.J. , Nov. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage biotechnology company focused on harnessing the power of
November 14, 2023
IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board
Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON’s FixPlas ™ and Indiplas ™ modalities in immuno-oncology. LAWRENCEVILLE, N.J. , Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing
October 6, 2023
IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET
Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J. , Sept. 13, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq:   IMNN) , a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and
September 13, 2023